Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,462.80
(
0.00%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
111.83
(
-0.48%
)
Bitcoin
76,045.51
(
0.36%
)
News Focus
News Focus
Post# of 823592
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 92
Posts 20563
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: biosectinvestor post# 559661

Sunday, 01/15/2023 12:25:30 PM

Sunday, January 15, 2023 12:25:30 PM

Post# of 823592

No, they did not say it was based on “data” from the trial...


They absolutely said that for OS the use of an ECA was based on the high crossover rate within the trial. That is data from the trial.

For PFS, they claim it is based on the new science of psPD and immuno agents. Problem is, this will be viewed with skepticism as they already knew the PFS endpoint was futile. Had the IA in 2015 shown the designed PFS endpoint was a success, they would not have changed it?
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News